BusinessEsperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability StudyBy Nasdaq OMXJan 13, 2016, 1:30 PM UTC
BusinessEsperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin TherapyBy Nasdaq OMXJan 12, 2016, 9:05 PM UTC
BusinessEsperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 6, 2016, 9:30 PM UTC
